 NEW HAVEN, Conn., Oct. 13, 2021 PRNewswire -- Trevi Therapeutics, Inc. Nasdaq: TRVI, a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy HaduvioTM nalbuphine ER to treat serious neurologically mediated conditions, today announced that Dr. Bill Forbes, Chief Development Officer, will present as part of a virtual viewpoint session at the 11th World Congress on Itch WCI taking place from October 22-23, 2021. 